ArticleCureus2026
Prolonged Cholestatic Hepatitis A With Transient Epstein-Barr Virus IgM Reactivity and Marked Hyperferritinemia in an HFE H63D Heterozygote.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis A virus (HAV) infection is usually self-limited and does not progress to chronic liver disease. However, atypical courses such as prolonged cholestatic hepatitis may occur in adults, posing diagnostic and therapeutic challenges. We report the case of a 55-year-old man with hypertension, obesity, and known hepatic steatosis who presented with jaundice, choluria, acholic stools, fatigue, epigastric pain, and nausea. Laboratory evaluation revealed a mixed hepatocellular-cholestatic pattern with predominantly direct hyperbilirubinemia. Acute HAV infection was confirmed (anti-HAV IgM positive), and alternative causes were excluded. Imaging showed no biliary obstruction. Epstein-Barr virus (EBV) serology obtained during the first admission was consistent with past infection (viral capsid antigen (VCA) IgG positive, VCA IgM negative, and EBV nuclear antigen-1 (EBNA-1) IgG positive). The patient improved with supportive care and was discharged after one week. He was readmitted one week later with clinical relapse and severe hyperbilirubinemia (total bilirubin 25.3 mg/dL). Given a household contact with a mononucleosis-like illness, repeat EBV serology showed weak/low-level VCA IgM reactivity (12.1 UA/mL) with persistent VCA IgG positivity. However, subsequent reassessment results returned to VCA IgM negativity with persistent VCA IgG and EBNA-1 IgG positivity, supporting remote EBV infection and suggesting non-specific IgM reactivity (or, less likely, reactivation) rather than primary acute EBV infection. EBV DNA PCR was not pursued due to low clinical and serologic suspicion of active infection and the subsequent resolving course. A genetic study requested during the first admission revealed HFE H63D heterozygosity, with a ferritin level >11,000 ng/mL and transferrin saturation of >80%. The patient improved with ursodeoxycholic acid (UDCA) and individualized iron management. Corticosteroids were not used, given progressive improvement with supportive care and UDCA. Follow-up quantitative liver MRI showed only mild iron overload (43 µmol/g), supporting an acute-phase/inflammatory iron contribution during severe hepatitis, and FibroScan® revealed mild fibrosis (5.3 kPa). This case highlights the importance of stepwise reassessment in prolonged cholestatic HAV, the pitfalls of interpreting transient EBV VCA IgM reactivity in a patient with serology consistent with prior EBV infection, and careful interpretation of marked hyperferritinemia in HFE H63D heterozygotes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.